Sonnet biotherapeutics announces successful completion of two ind-enabling toxicology studies with son-1210 in non-human primates

Son-1210 elicited no serious adverse events in repeat, subcutaneous dosing in a glp toxicology study son-1210 was well-tolerated using dosing levels at least 50x higher than the highest anticipated human clinical dose level data show controlled induction of ifng with no signs of cytokine release syndrome or off-target toxicity princeton, nj / accesswire / february 1, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) (the "company" or "sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that two ind-enabling toxicology studies have been completed in non-human primates (nhps) using its lead bifunctional therapeutic candidate. son-1210 is a proprietary, bispecific version of human interleukins 12 (il-12) and 15 (il-15), configured using sonnet's fully human albumin binding (fhab®) platform.
SONN Ratings Summary
SONN Quant Ranking